Galanin Peptide Research: GAL1, GAL2, and GAL3 Receptor Pharmacology and Preclinical Evidence

Galanin is a 29 amino acid neuropeptide (30 amino acids in humans) that acts as a co-transmitter and neuromodulator across the central and peripheral nervous systems. Research consistently demonstrates its inhibitory modulation of acetylcholine release in the hippocampus, its role in nociceptive signaling via dorsal root ganglia, and its bidirectional influence on feeding behavior through hypothalamic circuits. Three G protein-coupled receptors, GAL1, GAL2, and GAL3, mediate its effects, each with distinct signaling profiles and anatomical distributions that make galanin peptide research relevant to multiple investigative domains.

First isolated from porcine intestine by Tatemoto and colleagues in 1983, galanin was named for its N-terminal glycine and C-terminal alanine residues. The human variant contains an additional alanine at the C-terminus, making it 30 amino acids long, while the porcine and rat forms are 29 amino acids. Despite this structural difference, the N-terminal 1-15 fragment is considered the bioactive core responsible for receptor engagement across all three receptor subtypes. The peptide is encoded by the GAL gene and is subject to post-translational amidation at the C-terminus, a modification critical for receptor binding affinity.

GAL1, GAL2, and GAL3 Receptor Subtypes: Structural and Functional Distinctions

The three galanin receptors belong to the class A GPCR superfamily and were cloned sequentially during the 1990s. GAL1 was cloned in 1993 by Habert-Ortoli et al., GAL2 in 1996, and GAL3 in 1999. Despite sharing the same endogenous ligand, the three subtypes couple to different intracellular signaling cascades and show markedly different expression patterns.

GAL1 couples primarily to Gi/o proteins, leading to inhibition of adenylyl cyclase, reduction in cAMP levels, and activation of inwardly rectifying potassium channels (GIRK channels). This receptor subtype is highly expressed in the hippocampus, locus coeruleus, dorsal raphe nucleus, and spinal cord dorsal horn. Its inhibitory tone on noradrenergic neurons in the locus coeruleus has made it a subject of interest in mood disorder research. Mazarati and colleagues (2000, Journal of Neuroscience 20:6276-6281) compared galanin-knockout mice with mice overexpressing galanin under a dopamine beta-hydroxylase promoter: the knockouts were more prone to status epilepticus after perforant path stimulation or systemic kainic acid and to pentylenetetrazol convulsions, while the overexpressing mice resisted seizure induction in all three models. Depolarisation-induced glutamate release from hippocampal slices was greater in the knockouts and lower in the overexpressers, and long-term potentiation moved in the same directions, which identified modulation of glutamate release as the route by which hippocampal galanin acts as an endogenous anticonvulsant.

GAL2 demonstrates more complex signaling. It couples to both Gq proteins, stimulating phospholipase C, IP3 production, and intracellular calcium release, and Gi proteins depending on cell type and receptor density. GAL2 is expressed in the spinal cord, DRG neurons, and the gut, and several preclinical studies suggest it has pro-nociceptive properties that partially counteract the analgesic effects mediated by GAL1. Liu and Hökfelt (2002, Trends in Pharmacological Sciences 23:468-474) reviewed the receptor distribution and pain pharmacology at the spinal level, with a receptor-distribution map showing that GAL2 predominates in small-diameter DRG neurons (the C-fiber population associated with nociceptive transmission), while GAL1 is more prevalent in medium-to-large diameter neurons.

GAL3 is the least characterized subtype. It couples to Gi/o and is expressed at comparatively lower levels in the brain, with notable expression in the hypothalamus and anterior pituitary. Pharmacologically, GAL3 shows higher selectivity for the C-terminal region of galanin compared to GAL1 and GAL2, meaning that truncated galanin fragments can differentially activate GAL3 versus the other subtypes. SNAP 37889, a compound developed by Sanofi, became the first selective GAL3 antagonist to reach preclinical evaluation, and studies using this tool compound in 2005 demonstrated anxiolytic-like effects in rodent models (Swanson et al., PNAS, 2005).

Galanin in Pain Research: Spinal and Peripheral Mechanisms

The role of galanin in pain processing is one of the most extensively studied aspects of this peptide’s biology. Under basal conditions, galanin expression in DRG neurons is low. Following peripheral nerve injury, galanin mRNA and protein expression in DRG neurons increases dramatically, in some models by 100-fold within 48-72 hours of injury. This injury-induced upregulation is mediated by retrograde signaling involving nerve growth factor (NGF) and leukemia inhibitory factor (LIF).

The analgesic effects of galanin at the spinal level appear to be predominantly GAL1-mediated. Intrathecal administration of galanin in rat models of neuropathic pain (spinal nerve ligation models) reduces mechanical allodynia and thermal hyperalgesia. Wiesenfeld-Hallin and colleagues (1992, PNAS 89:3334-3337) used the high-affinity antagonist M-35, which displaced 125I-galanin from rat dorsal spinal cord membranes with an IC50 of 0.3 nM, to show that it dose-dependently blocked the effect of intrathecal galanin on the flexor reflex and by itself potentiated the reflex facilitation produced by conditioning stimulation of unmyelinated cutaneous afferents, an effect strongly enhanced after axotomy. Endogenous galanin therefore exerts a tonic inhibitory influence on spinal excitability that grows after peripheral nerve injury. The chimeric antagonists used in that era, M-35 and galantide (M15), are not subtype-selective; the GAL1 attribution of the analgesic effect rests on later work with subtype-preferring agonists, in which Liu and colleagues (2001, PNAS 98:9960-9964) showed that the GAL2-preferring fragment galanin(2-11) was pronociceptive at low concentrations while the full-length peptide acting through GAL1 was analgesic.

Peripheral galanin effects are more nuanced. In inflammatory pain models, exogenously applied galanin can potentiate nociceptor sensitization through GAL2 mechanisms, creating a context-dependent pharmacology where the net effect of galanin depends on the injury state, receptor subtype distribution, and anatomical site of action. This bidirectional quality has made galanin receptor pharmacology a subject of interest for selective agonist and antagonist development, where subtype specificity is critical for predictable outcomes in research models.

Hippocampal Galanin and Cholinergic Modulation: Relevance to Cognitive Research

One of galanin’s most reproducible preclinical findings involves its inhibitory regulation of acetylcholine release in the hippocampus. Galanin is co-stored with acetylcholine in a subset of medial septal/diagonal band neurons that project to the hippocampus via the septohippocampal pathway. When these neurons are activated, both acetylcholine and galanin are released, with galanin providing autoinhibitory feedback via GAL1 receptors on the same cholinergic neurons.

This co-transmission dynamic has significant implications for hippocampal-dependent memory research. Overexpression of galanin in transgenic mice produces measurable impairments in spatial memory tasks. Steiner and colleagues (2001, PNAS 98:4184-4189) generated transgenic mice overexpressing galanin under the dopamine beta-hydroxylase promoter and found a reduced number of identifiable acetylcholine-producing neurons in the horizontal limb of the diagonal band, together with selective deficits on the Morris spatial navigation task and the social transmission of food preference olfactory memory test, while general health, sensory and motor abilities were normal. The authors proposed that the galanin hyperinnervation of basal forebrain cholinergic neurons seen in Alzheimer’s disease contributes to the cognitive decline rather than merely accompanying it.

Conversely, galanin receptor knockout studies and pharmacological blockade with GAL1 antagonists in aged rodents and in models of cholinergic depletion have demonstrated improved acquisition in spatial memory tasks, supporting the concept that galanin’s tonic inhibition of cholinergic transmission represents a targetable mechanism. The relevance to Alzheimer’s disease research arises partly from postmortem findings showing marked upregulation of galanin fibers in the nucleus basalis of Meynert in human Alzheimer’s brain tissue (Chan-Palay et al., PNAS, 1990), suggesting a compensatory or pathological role in the cholinergic deficit that characterizes the disease.

Key Research Findings

Galanin-knockout mice are more seizure-prone and galanin-overexpressing mice more seizure-resistant, with hippocampal glutamate release moving in the opposite direction in each line (Mazarati et al., 2000). The high-affinity antagonist M-35 (IC50 0.3 nM at rat dorsal spinal cord membranes) blocks intrathecal galanin at the flexor reflex and unmasks a tonic inhibitory role for endogenous galanin that is strongly enhanced after axotomy (Wiesenfeld-Hallin et al., 1992), and the GAL2-preferring fragment galanin(2-11) is pronociceptive while full-length galanin acting through GAL1 is analgesic (Liu et al., 2001). Galanin-overexpressing transgenic mice lose identifiable cholinergic neurons in the horizontal limb of the diagonal band and show selective deficits in the Morris water maze and social transmission of food preference (Steiner et al., 2001). Galanin injected into the paraventricular nucleus preferentially increases fat intake, in contrast to neuropeptide Y, which drives carbohydrate intake (Tempel et al., 1988). The GAL3-selective antagonist SNAP 37889 produced anxiolytic-like and antidepressant-like profiles in rodent models (Swanson et al., 2005, PNAS 102:17489-17494). Peripheral nerve injury markedly upregulates galanin expression in dorsal root ganglion neurons, and postmortem Alzheimer’s brain tissue shows galanin hyperinnervation of surviving neurons in the nucleus basalis of Meynert (Chan-Palay, 1988).

Galanin in Feeding and Energy Metabolism Research

Hypothalamic galanin signaling has been studied extensively in the context of macronutrient preference and energy balance. Central administration of galanin specifically increases fat intake in rodent models without producing equivalent increases in carbohydrate or protein consumption, a selectivity that distinguishes it from other orexigenic neuropeptides such as neuropeptide Y (NPY), which broadly stimulates food intake. This macronutrient specificity is mediated at least in part through interactions with the paraventricular nucleus of the hypothalamus (PVN) and the ventromedial hypothalamus.

Tempel, Leibowitz and Leibowitz (1988, Peptides 9:309-314) showed that galanin injected into the paraventricular nucleus of satiated rats maintained on separate protein, carbohydrate and fat diets preferentially increased consumption of the fat diet, with a significantly smaller increase in carbohydrate intake and no change in protein intake; when the fat diet was removed, the stimulation of carbohydrate intake was selectively enhanced. Neuropeptide Y injected at the same site drove carbohydrate intake instead, which established that the two co-localised peptides act on macronutrient selection with different specificities. Subsequent work identified a positive feedback loop: dietary fat consumption itself upregulates galanin expression in hypothalamic neurons, creating a mechanism that may contribute to the entrainment of high-fat dietary preference in animal models. The relationship between galanin and insulin also warrants note: galanin inhibits insulin secretion from pancreatic beta cells through galanin receptors on the islet, a mechanism that links this neuropeptide to peripheral glucose metabolism research.

Galanin Fragments and Receptor Selectivity Tools

The galanin N-terminal fragment galanin(1-15) has emerged as a particularly interesting research tool because it exhibits selectivity for GAL1 and GAL2 while having markedly reduced affinity for GAL3. Even more intriguing is that galanin(1-15) potentiates serotonin 1A (5-HT1A) receptor signaling through a mechanism that appears to involve heteroreceptor complexes, a discovery from Fuxe and colleagues at the Karolinska Institute that opened a new dimension of galanin pharmacology extending beyond classical receptor engagement.

Two tool compounds are routinely confused. Galanin(2-11) is an N-terminal fragment of the peptide that behaves as a GAL2-preferring agonist and is the standard tool for separating GAL2 from GAL1 effects. Galnon is not a galanin fragment at all: it is a low-molecular-weight nonpeptide, 7-((9-fluorenylmethoxycarbonyl)cyclohexylalanyllysyl)amino-4-methylcoumarin, identified by Saar and colleagues (2002, PNAS 99:7136-7141) from a combinatorial library built on galanin pharmacophores. Galnon displaced 125I-galanin with micromolar affinity at Bowes cell and rat hippocampal membranes, inhibited adenylate cyclase, reduced the severity and increased the latency of pentylenetetrazole-induced seizures in mice after intraperitoneal injection, reversed the proconvulsant effect of intracerebroventricular M35, and shortened self-sustaining status epilepticus in rats after intrahippocampal injection; antisense knockdown of GAL1 abolished the anticonvulsant effect. Bartfai and colleagues (2004, PNAS 101:10470-10475) then displayed galnon’s presumed pharmacophores on a rigid scaffold to produce galmic, which has micromolar affinity for GAL1 (Ki 34.2 uM) and virtually none for GAL2, suppresses dentate gyrus long-term potentiation like galanin, blocks status epilepticus after intrahippocampal or intraperitoneal administration, and reduces formalin-induced flinching. Together these papers established that systemically active nonpeptide galanin agonists can reach central targets.

Analytical Considerations for Galanin Research

From an analytical standpoint, galanin’s 29-30 amino acid length places it in a size range where both HPLC and mass spectrometry are critical for purity verification. The peptide’s C-terminal amidation must be confirmed, unamidated galanin shows substantially reduced receptor affinity and is effectively a different compound. Researchers sourcing galanin for in vitro or animal model work should verify that certificates of analysis include both HPLC purity data reported to at least one decimal place and mass spectrometry confirmation of the correct molecular mass, including confirmation that the amide modification is present rather than a free acid at the C-terminus.

Where a batch of a compound in our catalogue has been tested, Maple Research Labs publishes the independent laboratory report on its certificates of analysis page, which also lists the compounds still awaiting a certificate. For compounds like galanin where post-translational modifications affect biological activity, COA verification of the correct molecular weight is particularly important. Researchers can review batch-specific documentation at our certificates of analysis page before placing orders. For related neuropeptide research, our full peptide catalog and compound documentation at the documentation portal provide additional research context.

Current Research Directions

Contemporary galanin research has expanded into several areas that were not accessible in earlier decades. The discovery of galanin-like peptide (GALP), a 60 amino acid peptide that contains the galanin(1-13) sequence within its structure and binds all three galanin receptors, has added complexity to the galanin signaling system. GALP is expressed primarily in the hypothalamic arcuate nucleus and pituitary and appears to modulate GnRH secretion, suggesting a role in reproductive neuroendocrinology distinct from the classical galanin effects.

Galanin’s interaction with the noradrenergic system, particularly at the locus coeruleus, has drawn interest in the context of stress and mood regulation research. The co-localization of galanin with norepinephrine in LC neurons and the inhibitory GAL1-mediated regulation of LC firing place galanin in a modulatory position within stress response circuitry. Transgenic models with altered galanin expression in LC neurons show changes in behavioral despair measures in forced swim and tail suspension tests, effects that are partially reversed by GAL2 agonism in some experimental contexts, revealing the receptor-subtype complexity that defines this peptide’s research landscape. For researchers building mechanistic context around hypothalamic neuropeptides, our summaries on neuropeptide Y and energy homeostasis and orexin-A receptor pharmacology provide complementary mechanistic reference points. Because galanin fragments are prone to truncation during synthesis, receptor-subtype work depends on verified peptide identity, which is why our overviews of HPLC purity testing and peptide impurity profiling are worth reading alongside any receptor pharmacology protocol.

Related research resources: further reading on somatostatin receptor research, VIP and VPAC receptor research, and substance P and NK1 receptor research.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use. All information is provided for educational and scientific research purposes.